University of Florida Research Foundation, Incorporated

Other

Amdl, Inc.

Lung-Ji Chang

Jan S Moreb

Scott A Rivkees

Christopher Wendler

Jin He

The disclosure provides chimeric antigen receptors (CARs), T cells comprising such CARs, nucleic acids that encode such CARS, and methods of use thereof, e.g., to treat cancer such as B cell malignancies.

Car based immunotherapy

Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.

Chimeric antigen receptors and uses thereof

Provided herein are chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., CD19, CD30, GD2, etc.), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, 4-1BB, etc.). In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods.

Provided herein are bi-specific chimeric antigen receptors (CARs), such as those specific for CD138 and BCMA. Use of the CARs in immune cells (e.g., T cells), compositions, and methods are also contemplated.

Bi-specific chimeric antigen receptor and uses thereof

Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.

Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells

Gene expression is inhibited in a cell by introducing into the cell a lentiviral vector encoding a siRNA specific for the gene. Lentiviral vectors encoding siRNA specific for a cancer-associated gene inhibited expression of the gene and caused cell death after being introduced into cancer cells. Viral replication in HIV-infected cells was inhibited after introducing a lentiviral vector encoding siRNA specific for HIV genes in into the cells.

Small interference RNA gene therapy

The present invention provides to immunogene therapy protocols for the treatment of tumors. In particular, the present invention provides combinations of immune-modulating proteins that induce systemic immunity against tumors. In addition, the present invention provides humanized animal models suitable for the evaluation of anti-human tumor immunity and permit the identification of combinations of immune-modulating genes which when delivered to human tumor cells induce an effective anti-tumor response, including a systemic anti-tumor response.

Combination immunogene therapy

The present invention contemplates novel lentiviral vectors which exhibit strong promoter activity in human and other cells. Vectors are provided which are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks. The present invention further relates to HIV vaccines and compositions for gene therapy. In particular, the present invention provides attenuated replication-competent HIV vaccines and replication defective HIV vectors.

Lentiviral vectors

The present invention provides animals and methods for the evaluation of vaccines. In particular, the present invention provides humanized animal models for the evaluation of vaccines designed to confer immunity against human pathogens, including vaccines directed against the human immunodeficiency virus. The present invention further relates to HIV vaccines. In particular, the present invention provides attenuated replication-competent HIV vaccines and replication-defective HIV vaccines. In addition, the invention provides modified Leishmania cells expressing HIV proteins.

Method of using mouse model for evaluation of HIV vaccines

The present invention contemplates novel lentiviral vectors which exhibit strong promoter activity in human and other cells. Vectors are provided which are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks. The present invention further relates to HIV vaccines and compositions for gene therapy. In particular, the present invention provides attenuated replication-competent HIV vaccines and replication-defective HIV vectors.

Growing community of inventors

Gainesville, FL, United States of America

Lung-Ji Chang